Review
. 2020 Jan; 21(2):.
doi: 10.3390/ijms21020597.

Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges

Kei Kunimasa 1 Taichiro Goto 2 
Affiliations
  • PMID: 31963413
  •     204 References
  •     21 citations

Abstract

The immune system plays a dual role in tumor evolution-it can identify and control nascent tumor cells in a process called immunosurveillance and can promote tumor progression through immunosuppression via various mechanisms. Thus, bilateral host-protective and tumor-promoting actions of immunity are integrated as cancer immunoediting. In this decade, immune checkpoint inhibitors, specifically programmed cell death 1 (PD-1) pathway inhibitors, have changed the treatment paradigm of advanced non-small cell lung cancer (NSCLC). These agents are approved for the treatment of patients with NSCLC and demonstrate impressive clinical activity and durable responses in some patients. However, for many NSCLC patients, the efficacy of immune checkpoint inhibitors is limited. To optimize the full utility of the immune system for eradicating cancer, a broader understanding of cancer immunosurveillance and immunoediting is essential. In this review, we discuss the fundamental knowledge of the phenomena and provide an overview of the next-generation immunotherapies in the pipeline.

Keywords: immune checkpoint inhibitors; immunoedition; immunotherapy; non-small cell lung cancer.

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
H Nishimura, T Okazaki, +8 authors, T Honjo.
Science, 2001 Feb 24; 291(5502). PMID: 11209085
Highly Cited.
Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery.
Kenta Narumi, Reina Miyakawa, +7 authors, Kazunori Aoki.
Sci Rep, 2019 Apr 05; 9(1). PMID: 30944344    Free PMC article.
Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma.
Takahide Nejo, Hirokazu Matsushita, +21 authors, Kazuhiro Kakimi.
Cancer Immunol Res, 2019 May 16; 7(7). PMID: 31088845
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, +18 authors, IMpower150 Study Group.
N Engl J Med, 2018 Jun 05; 378(24). PMID: 29863955
Highly Cited.
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Shannon L Maude, Theodore W Laetsch, +32 authors, Stephan A Grupp.
N Engl J Med, 2018 Feb 01; 378(5). PMID: 29385370    Free PMC article.
Highly Cited.
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
F Stephen Hodi, Marcus Butler, +17 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2008 Feb 22; 105(8). PMID: 18287062    Free PMC article.
Highly Cited.
How does the immune system learn to distinguish between good and evil? The first definitive studies of T cell central tolerance and positive selection.
Paweł Kisielow.
Immunogenetics, 2019 Aug 17; 71(8-9). PMID: 31418051    Free PMC article.
Review.
Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.
Z K Klippel, J Chou, +4 authors, E H Warren.
Gene Ther, 2014 Jan 24; 21(3). PMID: 24451117    Free PMC article.
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
Leora Horn, David R Spigel, +26 authors, Wilfried E E Eberhardt.
J Clin Oncol, 2017 Oct 13; 35(35). PMID: 29023213    Free PMC article.
Highly Cited.
Dendritic cells in cancer immunology and immunotherapy.
Stefanie K Wculek, Francisco J Cueto, +3 authors, David Sancho.
Nat Rev Immunol, 2019 Aug 31; 20(1). PMID: 31467405
Highly Cited. Review.
Targeting neoantigens for cancer immunotherapy.
Yong-Chen Lu, Paul F Robbins.
Int Immunol, 2016 May 22; 28(7). PMID: 27208041    Free PMC article.
Review.
Pembrolizumab plus Chemotherapy in Lung Cancer.
Leena Gandhi, Marina C Garassino.
N Engl J Med, 2018 Sep 13; 379(11). PMID: 30207917
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.
Yannick Simoni, Etienne Becht, +29 authors, Evan W Newell.
Nature, 2018 May 18; 557(7706). PMID: 29769722
Highly Cited.
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.
Samuel J Klempner, David Fabrizio, +8 authors, Prasanth Reddy.
Oncologist, 2019 Oct 04; 25(1). PMID: 31578273    Free PMC article.
Review.
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
Robert D Schreiber, Lloyd J Old, Mark J Smyth.
Science, 2011 Mar 26; 331(6024). PMID: 21436444
Highly Cited. Review.
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, +18 authors, Timothy A Chan.
N Engl J Med, 2014 Nov 20; 371(23). PMID: 25409260    Free PMC article.
Highly Cited.
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.
Padmanee Sharma, Klaus Wagner, Jedd D Wolchok, James P Allison.
Nat Rev Cancer, 2011 Oct 25; 11(11). PMID: 22020206    Free PMC article.
Highly Cited. Review.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Bernard Escudier, +25 authors, CheckMate 025 Investigators.
N Engl J Med, 2015 Sep 26; 373(19). PMID: 26406148    Free PMC article.
Highly Cited.
Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation.
Yasushi Onishi, Zoltan Fehervari, Tomoyuki Yamaguchi, Shimon Sakaguchi.
Proc Natl Acad Sci U S A, 2008 Jul 19; 105(29). PMID: 18635688    Free PMC article.
Highly Cited.
Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release.
Shu Lian, Ruizhi Xie, +7 authors, Lee Jia.
EBioMedicine, 2019 Mar 18; 42. PMID: 30878596    Free PMC article.
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment.
Joel Crespo, Haoyu Sun, +2 authors, Weiping Zou.
Curr Opin Immunol, 2013 Jan 10; 25(2). PMID: 23298609    Free PMC article.
Highly Cited. Review.
Spatiotemporal regulation of clonogenicity in colorectal cancer xenografts.
Maartje van der Heijden, Daniël M Miedema, +17 authors, Louis Vermeulen.
Proc Natl Acad Sci U S A, 2019 Mar 10; 116(13). PMID: 30850544    Free PMC article.
Crosstalk between cancer and immune cells: Role of tumor-associated macrophages in the tumor microenvironment.
Jing Wang, Danyang Li, Huaixing Cang, Bo Guo.
Cancer Med, 2019 Jun 22; 8(10). PMID: 31222971    Free PMC article.
Highly Cited. Review.
Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin.
David Sancho, Diego Mourão-Sá, +5 authors, Caetano Reis e Sousa.
J Clin Invest, 2008 May 24; 118(6). PMID: 18497879    Free PMC article.
Highly Cited.
Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges.
Taichiro Goto.
Vaccines (Basel), 2019 Aug 29; 7(3). PMID: 31455032    Free PMC article.
Review.
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Scott J Antonia, Hossein Borghaei, +17 authors, Julie Brahmer.
Lancet Oncol, 2019 Aug 20; 20(10). PMID: 31422028    Free PMC article.
Highly Cited.
Immune checkpoint inhibitors: recent progress and potential biomarkers.
Pramod Darvin, Salman M Toor, Varun Sasidharan Nair, Eyad Elkord.
Exp Mol Med, 2018 Dec 14; 50(12). PMID: 30546008    Free PMC article.
Highly Cited. Review.
Immune evasion in cancer: Mechanistic basis and therapeutic strategies.
Dass S Vinay, Elizabeth P Ryan, +29 authors, Byoung S Kwon.
Semin Cancer Biol, 2015 Mar 31; 35 Suppl. PMID: 25818339
Highly Cited. Review.
Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy.
E Y Lin, A V Nguyen, R G Russell, J W Pollard.
J Exp Med, 2001 Mar 21; 193(6). PMID: 11257139    Free PMC article.
Highly Cited.
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
Rebecca Leyland, Amanda Watkins, +19 authors, Ross Stewart.
Clin Cancer Res, 2017 Jan 11; 23(13). PMID: 28069723
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, +21 authors, Timothy A Chan.
Science, 2015 Mar 15; 348(6230). PMID: 25765070    Free PMC article.
Highly Cited.
Control of regulatory T cell development by the transcription factor Foxp3.
Shohei Hori, Takashi Nomura, Shimon Sakaguchi.
Science, 2003 Jan 11; 299(5609). PMID: 12522256
Highly Cited.
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.
Kevin C Barry, Joy Hsu, +19 authors, Matthew F Krummel.
Nat Med, 2018 Jun 27; 24(8). PMID: 29942093    Free PMC article.
Highly Cited.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
Ranjana Advani, Ian Flinn, +18 authors, Sonali M Smith.
N Engl J Med, 2018 Nov 01; 379(18). PMID: 30380386    Free PMC article.
Highly Cited.
Macrophage diversity enhances tumor progression and metastasis.
Bin-Zhi Qian, Jeffrey W Pollard.
Cell, 2010 Apr 08; 141(1). PMID: 20371344    Free PMC article.
Highly Cited. Review.
Multiple mutations and cancer.
Lawrence A Loeb, Keith R Loeb, Jon P Anderson.
Proc Natl Acad Sci U S A, 2003 Jan 29; 100(3). PMID: 12552134    Free PMC article.
Highly Cited. Review.
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Patrick M Forde, Jamie E Chaft, Drew M Pardoll.
N Engl J Med, 2018 Aug 30; 379(9). PMID: 30157404
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.
Stefano Ugel, Francesco De Sanctis, Susanna Mandruzzato, Vincenzo Bronte.
J Clin Invest, 2015 Sep 02; 125(9). PMID: 26325033    Free PMC article.
Highly Cited. Review.
MHC-I Genotype Restricts the Oncogenic Mutational Landscape.
Rachel Marty, Saghar Kaabinejadian, +8 authors, Hannah Carter.
Cell, 2017 Nov 07; 171(6). PMID: 29107334    Free PMC article.
Highly Cited.
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
J Shimizu, S Yamazaki, S Sakaguchi.
J Immunol, 1999 Nov 24; 163(10). PMID: 10553041
Highly Cited.
Immunogenic neoantigens derived from gene fusions stimulate T cell responses.
Wei Yang, Ken-Wing Lee, +31 authors, Luc G T Morris.
Nat Med, 2019 Apr 24; 25(5). PMID: 31011208    Free PMC article.
Highly Cited.
Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.
Rajarsi Mandal, Robert M Samstein, +21 authors, Timothy A Chan.
Science, 2019 May 03; 364(6439). PMID: 31048490    Free PMC article.
Highly Cited.
Role of CD47 as a marker of self on red blood cells.
P A Oldenborg, A Zheleznyak, +3 authors, F P Lindberg.
Science, 2000 Jun 17; 288(5473). PMID: 10856220
Highly Cited.
Chimeric Antigen Receptor Therapy.
Carl H June, Michel Sadelain.
N Engl J Med, 2018 Jul 05; 379(1). PMID: 29972754    Free PMC article.
Highly Cited. Review.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Tracking the Evolution of Non-Small-Cell Lung Cancer.
Mariam Jamal-Hanjani, Gareth A Wilson, +81 authors, TRACERx Consortium.
N Engl J Med, 2017 Apr 27; 376(22). PMID: 28445112
Highly Cited.
Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy.
Yoshihiro Komohara, Yukio Fujiwara, Koji Ohnishi, Motohiro Takeya.
Adv Drug Deliv Rev, 2015 Dec 02; 99(Pt B). PMID: 26621196
Highly Cited. Review.
Clinical trials of CAR-T cells in China.
Bingshan Liu, Yongping Song, Delong Liu.
J Hematol Oncol, 2017 Oct 24; 10(1). PMID: 29058636    Free PMC article.
Highly Cited.
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Martin Reck, Tony S K Mok, +18 authors, IMpower150 Study Group.
Lancet Respir Med, 2019 Mar 30; 7(5). PMID: 30922878
Highly Cited.
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination.
Chih-Wen Tseng, Chien-Fu Hung, +9 authors, T-C Wu.
Clin Cancer Res, 2008 May 17; 14(10). PMID: 18483387    Free PMC article.
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Timothy M Nywening, Andrea Wang-Gillam, +18 authors, David C Linehan.
Lancet Oncol, 2016 Apr 09; 17(5). PMID: 27055731    Free PMC article.
Highly Cited.
Regulation of adaptive immunity by the innate immune system.
Akiko Iwasaki, Ruslan Medzhitov.
Science, 2010 Jan 16; 327(5963). PMID: 20075244    Free PMC article.
Highly Cited. Review.
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.
V Shankaran, H Ikeda, +4 authors, R D Schreiber.
Nature, 2001 Apr 27; 410(6832). PMID: 11323675
Highly Cited.
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Luis Paz-Ares, Alexander Luft, +20 authors, KEYNOTE-407 Investigators.
N Engl J Med, 2018 Oct 04; 379(21). PMID: 30280635
Highly Cited.
Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma.
Akash M Mehta, Ekaterina S Jordanova, +2 authors, Gert-Jan Fleuren.
Cancer Immunol Immunother, 2007 Jul 12; 57(2). PMID: 17622526    Free PMC article.
High frequency of allele-specific down-regulation of HLA class I expression in lung cancer cell lines.
Akio Hiraki, Nobuharu Fujii, +9 authors, Mine Harada.
Anticancer Res, 2004 Jul 28; 24(3a). PMID: 15274319
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
Joannes F M Jacobs, Stefan Nierkens, +2 authors, Gosse J Adema.
Lancet Oncol, 2012 Jan 10; 13(1). PMID: 22225723
Review.
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.
Mahesh Yadav, Suchit Jhunjhunwala, +11 authors, Lélia Delamarre.
Nature, 2014 Nov 28; 515(7528). PMID: 25428506
Highly Cited.
Tumor-associated macrophages: functional diversity, clinical significance, and open questions.
Subhra K Biswas, Paola Allavena, Alberto Mantovani.
Semin Immunopathol, 2013 May 10; 35(5). PMID: 23657835
Highly Cited. Review.
Comprehensive molecular profiling of lung adenocarcinoma.
Cancer Genome Atlas Research Network.
Nature, 2014 Aug 01; 511(7511). PMID: 25079552    Free PMC article.
Highly Cited.
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications.
Mark P Chao, Irving L Weissman, Ravindra Majeti.
Curr Opin Immunol, 2012 Feb 09; 24(2). PMID: 22310103    Free PMC article.
Highly Cited. Review.
Functional polarization of tumour-associated macrophages by tumour-derived lactic acid.
Oscar R Colegio, Ngoc-Quynh Chu, +10 authors, Ruslan Medzhitov.
Nature, 2014 Jul 22; 513(7519). PMID: 25043024    Free PMC article.
Highly Cited.
Mutational analysis of multiple lung cancers: Discrimination between primary and metastatic lung cancers by genomic profile.
Taichiro Goto, Yosuke Hirotsu, +7 authors, Masao Omata.
Oncotarget, 2017 Apr 19; 8(19). PMID: 28415711    Free PMC article.
Tumor regulatory T cells potently abrogate antitumor immunity.
Zuqiang Liu, Jin H Kim, Louis D Falo, Zhaoyang You.
J Immunol, 2009 May 06; 182(10). PMID: 19414769    Free PMC article.
Phagocytosis checkpoints as new targets for cancer immunotherapy.
Mingye Feng, Wen Jiang, +3 authors, Irving L Weissman.
Nat Rev Cancer, 2019 Aug 30; 19(10). PMID: 31462760    Free PMC article.
Highly Cited. Review.
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.
Takeo Nomi, Masayuki Sho, +8 authors, Yoshiyuki Nakajima.
Clin Cancer Res, 2007 Apr 04; 13(7). PMID: 17404099
Highly Cited.
Cancer genome landscapes.
Bert Vogelstein, Nickolas Papadopoulos, +3 authors, Kenneth W Kinzler.
Science, 2013 Mar 30; 339(6127). PMID: 23539594    Free PMC article.
Highly Cited. Review.
CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages.
Takanori Kitamura, Bin-Zhi Qian, +6 authors, Jeffrey W Pollard.
J Exp Med, 2015 Jun 10; 212(7). PMID: 26056232    Free PMC article.
Highly Cited.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
Regulatory T cells: how do they suppress immune responses?
Shimon Sakaguchi, Kajsa Wing, +2 authors, Tomoyuki Yamaguchi.
Int Immunol, 2009 Sep 10; 21(10). PMID: 19737784
Highly Cited. Review.
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
Christian Blank, Juergen Kuball, +8 authors, Andreas Mackensen.
Int J Cancer, 2006 Feb 17; 119(2). PMID: 16482562
Highly Cited.
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
Vinod P Balachandran, Marta Łuksza, +56 authors, Steven D Leach.
Nature, 2017 Nov 14; 551(7681). PMID: 29132146    Free PMC article.
Highly Cited.
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Y Ishida, Y Agata, K Shibahara, T Honjo.
EMBO J, 1992 Nov 01; 11(11). PMID: 1396582    Free PMC article.
Highly Cited.
Cancer immunoediting and resistance to T cell-based immunotherapy.
Jake S O'Donnell, Michele W L Teng, Mark J Smyth.
Nat Rev Clin Oncol, 2018 Dec 12; 16(3). PMID: 30523282
Highly Cited. Review.
Phagocytosis: at the crossroads of innate and adaptive immunity.
Isabelle Jutras, Michel Desjardins.
Annu Rev Cell Dev Biol, 2005 Oct 11; 21. PMID: 16212505
Review.
Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.
Madhav V Dhodapkar, Mario Sznol, +16 authors, Tibor Keler.
Sci Transl Med, 2014 Apr 18; 6(232). PMID: 24739759    Free PMC article.
Highly Cited.
Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies.
Milos Aleksic, Nathaniel Liddy, +4 authors, Bent K Jakobsen.
Eur J Immunol, 2012 Sep 06; 42(12). PMID: 22949370    Free PMC article.
Highly Cited.
Emerging therapies for non-small cell lung cancer.
Chao Zhang, Natasha B Leighl, Yi-Long Wu, Wen-Zhao Zhong.
J Hematol Oncol, 2019 Apr 27; 12(1). PMID: 31023335    Free PMC article.
Highly Cited. Review.
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens.
Volker Lennerz, Martina Fatho, +6 authors, Thomas Wölfel.
Proc Natl Acad Sci U S A, 2005 Oct 26; 102(44). PMID: 16247014    Free PMC article.
Highly Cited.
T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells.
M P Tan, A B Gerry, +8 authors, A K Sewell.
Clin Exp Immunol, 2014 Dec 17; 180(2). PMID: 25496365    Free PMC article.
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
H Nishimura, M Nose, +2 authors, T Honjo.
Immunity, 1999 Sep 15; 11(2). PMID: 10485649
Highly Cited.
Tipping the balance: inhibitory checkpoints in intestinal homeostasis.
Maria E Joosse, Iris Nederlof, Lucy S K Walker, Janneke N Samsom.
Mucosal Immunol, 2018 Dec 01; 12(1). PMID: 30498201
Review.
Human Tumor Antigens and Cancer Immunotherapy.
Nathalie Vigneron.
Biomed Res Int, 2015 Jul 15; 2015. PMID: 26161423    Free PMC article.
Review.
FOXP3+ regulatory T cells in the human immune system.
Shimon Sakaguchi, Makoto Miyara, Cristina M Costantino, David A Hafler.
Nat Rev Immunol, 2010 Jun 19; 10(7). PMID: 20559327
Highly Cited. Review.
Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy.
E M G van Esch, B Tummers, +11 authors, E S Jordanova.
Int J Cancer, 2014 Jan 15; 135(4). PMID: 24415578
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, +16 authors, KEYNOTE-024 Investigators.
N Engl J Med, 2016 Oct 11; 375(19). PMID: 27718847
Highly Cited.
Adaptive Immune Resistance: How Cancer Protects from Immune Attack.
Antoni Ribas.
Cancer Discov, 2015 Aug 15; 5(9). PMID: 26272491    Free PMC article.
Highly Cited. Review.
Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells.
Takashi Inozume, Ken-Ichi Hanada, +4 authors, James C Yang.
J Immunother, 2010 Oct 16; 33(9). PMID: 20948441    Free PMC article.
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story.
D J Hicklin, F M Marincola, S Ferrone.
Mol Med Today, 1999 May 18; 5(4). PMID: 10203751
Review.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, +23 authors, OAK Study Group.
Lancet, 2016 Dec 17; 389(10066). PMID: 27979383    Free PMC article.
Highly Cited.
Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization.
Ruka Setoguchi, Shohei Hori, Takeshi Takahashi, Shimon Sakaguchi.
J Exp Med, 2005 Mar 09; 201(5). PMID: 15753206    Free PMC article.
Highly Cited.
CTLA-4 control over Foxp3+ regulatory T cell function.
Kajsa Wing, Yasushi Onishi, +5 authors, Shimon Sakaguchi.
Science, 2008 Oct 11; 322(5899). PMID: 18845758
Highly Cited.
Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape.
Abhishek D Garg, Pierre G Coulie, Benoit J Van den Eynde, Patrizia Agostinis.
Trends Immunol, 2017 Jun 15; 38(8). PMID: 28610825
Highly Cited. Review.
Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.
Kalijn F Bol, Gerty Schreibelt, +2 authors, Carl G Figdor.
Clin Cancer Res, 2016 Apr 17; 22(8). PMID: 27084743
Highly Cited. Review.
Regulatory T cells and immune tolerance.
Shimon Sakaguchi, Tomoyuki Yamaguchi, Takashi Nomura, Masahiro Ono.
Cell, 2008 May 31; 133(5). PMID: 18510923
Highly Cited. Review.
Pulmonary alveolar macrophages contribute to the premetastatic niche by suppressing antitumor T cell responses in the lungs.
Sharad K Sharma, Navin K Chintala, +3 authors, Maciej M Markiewski.
J Immunol, 2015 Apr 26; 194(11). PMID: 25911761
In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination.
Laura C Bonifaz, David P Bonnyay, +7 authors, Ralph M Steinman.
J Exp Med, 2004 Mar 17; 199(6). PMID: 15024047    Free PMC article.
Highly Cited.
Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies.
Daniela F Quail, Johanna A Joyce.
Clin Cancer Res, 2016 Nov 30; 23(4). PMID: 27895033    Free PMC article.
Review.
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.
A A Hurwitz, T F Yu, D R Leach, J P Allison.
Proc Natl Acad Sci U S A, 1998 Aug 26; 95(17). PMID: 9707601    Free PMC article.
Highly Cited.
Pembrolizumab for the treatment of non-small-cell lung cancer.
Edward B Garon, Naiyer A Rizvi, +25 authors, KEYNOTE-001 Investigators.
N Engl J Med, 2015 Apr 22; 372(21). PMID: 25891174
Highly Cited.
Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.
Mansi Saxena, Nina Bhardwaj.
Trends Cancer, 2018 Feb 21; 4(2). PMID: 29458962    Free PMC article.
Highly Cited. Review.
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.
Martin Sebastian, Andreas Schröder, +23 authors, Sven D Koch.
Cancer Immunol Immunother, 2019 Feb 17; 68(5). PMID: 30770959
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Martin Reck, Delvys Rodríguez-Abreu, +15 authors, Julie R Brahmer.
J Clin Oncol, 2019 Jan 09; 37(7). PMID: 30620668
Highly Cited.
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
Eric Tran, Paul F Robbins, +9 authors, Steven A Rosenberg.
N Engl J Med, 2016 Dec 14; 375(23). PMID: 27959684    Free PMC article.
Highly Cited.
Agonist antibodies to TNFR molecules that costimulate T and NK cells.
Ignacio Melero, Daniel Hirschhorn-Cymerman, +2 authors, Jedd D Wolchok.
Clin Cancer Res, 2013 Mar 06; 19(5). PMID: 23460535    Free PMC article.
Highly Cited.
Rationale for anti-GITR cancer immunotherapy.
Deborah A Knee, Becker Hewes, Jennifer L Brogdon.
Eur J Cancer, 2016 Sep 04; 67. PMID: 27591414
Highly Cited. Review.
CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer.
Shingo Maeda, Kohei Murakami, +2 authors, Naoaki Matsuki.
Cancer Immunol Res, 2019 Jun 05; 7(7). PMID: 31160277
Stereotactic Radiotherapy for Oligometastasis.
Sotaro Otake, Taichiro Goto.
Cancers (Basel), 2019 Jan 27; 11(2). PMID: 30678111    Free PMC article.
Review.
Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy.
Silvie Cloosen, Janna Arnold, +3 authors, Wilfred T V Germeraad.
Cancer Res, 2007 Apr 19; 67(8). PMID: 17440107
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
Eric Tran, Simon Turcotte, +10 authors, Steven A Rosenberg.
Science, 2014 May 09; 344(6184). PMID: 24812403    Free PMC article.
Highly Cited.
Immune response regulation in the tumor microenvironment by hypoxia.
Sara Labiano, Asis Palazon, Ignacio Melero.
Semin Oncol, 2015 May 13; 42(3). PMID: 25965356
Review.
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Scott Antonia, Sarah B Goldberg, +8 authors, Naiyer A Rizvi.
Lancet Oncol, 2016 Feb 10; 17(3). PMID: 26858122    Free PMC article.
Highly Cited.
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
Valsamo Anagnostou, Kellie N Smith, +26 authors, Victor E Velculescu.
Cancer Discov, 2016 Dec 30; 7(3). PMID: 28031159    Free PMC article.
Highly Cited.
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
Kroopa Joshi, Marc Robert de Massy, +32 authors, Benny Chain.
Nat Med, 2019 Oct 09; 25(10). PMID: 31591606    Free PMC article.
The role of SHIP1 in macrophage programming and activation.
M J Rauh, L M Sly, +4 authors, G Krystal.
Biochem Soc Trans, 2004 Oct 21; 32(Pt 5). PMID: 15494015
Review.
Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.
Juliana Idoyaga, Ashira Lubkin, +8 authors, Ralph M Steinman.
Proc Natl Acad Sci U S A, 2011 Jan 26; 108(6). PMID: 21262813    Free PMC article.
Highly Cited.
Novel Immunotherapy Combinations.
Babar Bashir, Melissa A Wilson.
Curr Oncol Rep, 2019 Nov 07; 21(11). PMID: 31696332
Review.
The susceptibility to cytotoxic T lymphocyte mediated lysis of chemically induced sarcomas from immunodeficient and normal mice.
I M Svane, A M Engel, A R Thomsen, O Werdelin.
Scand J Immunol, 1997 Jan 01; 45(1). PMID: 9010497
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.
Paul F Robbins, Yong-Chen Lu, +9 authors, Steven A Rosenberg.
Nat Med, 2013 May 07; 19(6). PMID: 23644516    Free PMC article.
Highly Cited.
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer.
Nikolaos Zacharakis, Harshini Chinnasamy, +15 authors, Steven A Feldman.
Nat Med, 2018 Jun 06; 24(6). PMID: 29867227    Free PMC article.
Highly Cited.
Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases.
Natasa Strbo, Arlene Garcia-Soto, Taylor H Schreiber, Eckhard R Podack.
Immunol Res, 2013 Nov 21; 57(1-3). PMID: 24254084
Review.
Evolution of Metastases in Space and Time under Immune Selection.
Mihaela Angelova, Bernhard Mlecnik, +16 authors, Jérôme Galon.
Cell, 2018 Oct 16; 175(3). PMID: 30318143
Highly Cited.
The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages.
Daria Capece, Mariafausta Fischietti, +5 authors, Edoardo Alesse.
Biomed Res Int, 2013 Mar 28; 2013. PMID: 23533994    Free PMC article.
Highly Cited. Review.
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Matthew D Hellmann, Tudor-Eliade Ciuleanu, +21 authors, Luis Paz-Ares.
N Engl J Med, 2018 Apr 17; 378(22). PMID: 29658845    Free PMC article.
Highly Cited.
Cancer Evolution Constrained by the Immune Microenvironment.
Nicholas McGranahan, Charles Swanton.
Cell, 2017 Aug 26; 170(5). PMID: 28841415
The interaction properties of costimulatory molecules revisited.
Alison V Collins, Douglas W Brodie, +6 authors, Simon J Davis.
Immunity, 2002 Aug 28; 17(2). PMID: 12196291
Highly Cited.
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2019 Sep 29; 381(16). PMID: 31562797
Highly Cited.
Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections.
Tsvetelina Pentcheva-Hoang, Emily Corse, James P Allison.
Immunol Rev, 2009 May 12; 229(1). PMID: 19426215
Review.
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
Ramaswamy Govindan, Aleksandra Szczesna, +19 authors, Martin Reck.
J Clin Oncol, 2017 Aug 31; 35(30). PMID: 28854067
Highly Cited.
Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression.
Tomoyuki Yamaguchi, Ayumi Kishi, +5 authors, Shimon Sakaguchi.
Proc Natl Acad Sci U S A, 2013 May 22; 110(23). PMID: 23690575    Free PMC article.
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms.
Rumi Higuchi, Taichiro Goto, +6 authors, Masao Omata.
J Clin Med, 2019 Nov 07; 8(11). PMID: 31683962    Free PMC article.
Long-lived self-renewing bone marrow-derived macrophages displace embryo-derived cells to inhabit adult serous cavities.
Calum C Bain, Catherine A Hawley, +9 authors, Stephen J Jenkins.
Nat Commun, 2016 Jun 14; 7. PMID: 27292029    Free PMC article.
Highly Cited.
Epitope landscape in breast and colorectal cancer.
Neil H Segal, D Williams Parsons, +4 authors, James P Allison.
Cancer Res, 2008 Feb 05; 68(3). PMID: 18245491
Highly Cited.
The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.
Edward F McCarthy.
Iowa Orthop J, 2006 Jun 23; 26. PMID: 16789469    Free PMC article.
Highly Cited.
Macrophage-Mediated Subversion of Anti-Tumour Immunity.
Valeria Quaranta, Michael C Schmid.
Cells, 2019 Jul 25; 8(7). PMID: 31331034    Free PMC article.
Review.
Decoding the patterns of self and nonself by the innate immune system.
Ruslan Medzhitov, Charles A Janeway.
Science, 2002 Apr 16; 296(5566). PMID: 11951031
Highly Cited.
Rebalancing Immune Homeostasis to Treat Autoimmune Diseases.
David A Horwitz, Tarek M Fahmy, Ciriaco A Piccirillo, Antonio La Cava.
Trends Immunol, 2019 Oct 12; 40(10). PMID: 31601519    Free PMC article.
Review.
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
Mark Yarchoan, Alexander Hopkins, Elizabeth M Jaffee.
N Engl J Med, 2017 Dec 21; 377(25). PMID: 29262275    Free PMC article.
Highly Cited.
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.
Bin-Zhi Qian, Jiufeng Li, +6 authors, Jeffrey W Pollard.
Nature, 2011 Jun 10; 475(7355). PMID: 21654748    Free PMC article.
Highly Cited.
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.
Scott D Brown, Rene L Warren, +4 authors, Robert A Holt.
Genome Res, 2014 May 02; 24(5). PMID: 24782321    Free PMC article.
Highly Cited.
NeoFuse: predicting fusion neoantigens from RNA sequencing data.
Georgios Fotakis, Dietmar Rieder, +2 authors, Francesca Finotello.
Bioinformatics, 2019 Nov 23; 36(7). PMID: 31755900    Free PMC article.
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.
Margaret K Callahan, Jedd D Wolchok, James P Allison.
Semin Oncol, 2010 Nov 16; 37(5). PMID: 21074063    Free PMC article.
Review.
Molecular and cellular insights into T cell exhaustion.
E John Wherry, Makoto Kurachi.
Nat Rev Immunol, 2015 Jul 25; 15(8). PMID: 26205583    Free PMC article.
Highly Cited. Review.
Alloactivation of Naïve CD4+CD8-CD25+T Regulatory Cells: Expression of CD8α Identifies Potent Suppressor Cells That Can Promote Transplant Tolerance Induction.
Nirupama D Verma, Catherine M Robinson, +9 authors, Bruce M Hall.
Front Immunol, 2019 Nov 05; 10. PMID: 31681288    Free PMC article.
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Corey J Langer, Shirish M Gadgeel, +17 authors, KEYNOTE-021 investigators.
Lancet Oncol, 2016 Oct 18; 17(11). PMID: 27745820    Free PMC article.
Highly Cited.
The PD-1 pathway in tolerance and autoimmunity.
Loise M Francisco, Peter T Sage, Arlene H Sharpe.
Immunol Rev, 2010 Jul 20; 236. PMID: 20636820    Free PMC article.
Highly Cited. Review.
OX40 is a potent immune-stimulating target in late-stage cancer patients.
Brendan D Curti, Magdalena Kovacsovics-Bankowski, +20 authors, Andrew D Weinberg.
Cancer Res, 2013 Nov 02; 73(24). PMID: 24177180    Free PMC article.
Highly Cited.
Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection.
Cristiana Guiducci, Alain P Vicari, +2 authors, Mario P Colombo.
Cancer Res, 2005 Apr 19; 65(8). PMID: 15833879
Highly Cited.
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.
Gabriela Bindea, Bernhard Mlecnik, +14 authors, Jérôme Galon.
Immunity, 2013 Oct 22; 39(4). PMID: 24138885
Highly Cited.
The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research.
H C NAUTS, W E SWIFT, B L COLEY.
Cancer Res, 1946 Apr 01; 6. PMID: 21018724
Highly Cited.
CTLA-4 ligation blocks CD28-dependent T cell activation.
T L Walunas, C Y Bakker, J A Bluestone.
J Exp Med, 1996 Jun 01; 183(6). PMID: 8676075    Free PMC article.
Highly Cited.
Cancer immunotherapy comes of age.
Ira Mellman, George Coukos, Glenn Dranoff.
Nature, 2011 Dec 24; 480(7378). PMID: 22193102    Free PMC article.
Highly Cited. Review.
Tumor mutation burden: from comprehensive mutational screening to the clinic.
Francesca Galuppini, Carlo Alberto Dal Pozzo, +3 authors, Raffaele Baffa.
Cancer Cell Int, 2019 Aug 14; 19. PMID: 31406485    Free PMC article.
Review.
Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class.
W Caleb Rutledge, Jun Kong, +16 authors, Daniel J Brat.
Clin Cancer Res, 2013 Jul 19; 19(18). PMID: 23864165    Free PMC article.
Regulatory T cells in cancer immunotherapy.
Hiroyoshi Nishikawa, Shimon Sakaguchi.
Curr Opin Immunol, 2014 Jan 15; 27. PMID: 24413387
Highly Cited. Review.
TNF superfamily in inflammatory disease: translating basic insights.
Michael Croft, Wei Duan, +3 authors, Amit Mehta.
Trends Immunol, 2011 Dec 16; 33(3). PMID: 22169337    Free PMC article.
Review.
Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
Takemasa Tsuji, Junko Matsuzaki, +8 authors, Sacha Gnjatic.
J Immunol, 2010 Dec 15; 186(2). PMID: 21149605
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Oncology meets immunology: the cancer-immunity cycle.
Daniel S Chen, Ira Mellman.
Immunity, 2013 Jul 31; 39(1). PMID: 23890059
Highly Cited. Review.
Regulatory T cells in tumor immunity.
Hiroyoshi Nishikawa, Shimon Sakaguchi.
Int J Cancer, 2010 Jun 03; 127(4). PMID: 20518016
Highly Cited. Review.
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.
Ryosuke Hino, Kenji Kabashima, +5 authors, Yoshiki Tokura.
Cancer, 2010 Feb 10; 116(7). PMID: 20143437
Highly Cited.
On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.
Alexander M Lesokhin, Margaret K Callahan, Michael A Postow, Jedd D Wolchok.
Sci Transl Med, 2015 Mar 27; 7(280). PMID: 25810313
Highly Cited. Review.
Cancer immunotherapies targeting the PD-1 signaling pathway.
Yoshiko Iwai, Junzo Hamanishi, Kenji Chamoto, Tasuku Honjo.
J Biomed Sci, 2017 Apr 06; 24(1). PMID: 28376884    Free PMC article.
Highly Cited. Review.
The Intersection between Tumor Angiogenesis and Immune Suppression.
Osama E Rahma, F Stephen Hodi.
Clin Cancer Res, 2019 Apr 05; 25(18). PMID: 30944124
Review.
CAR T-Cell Therapy in Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, William Y Go.
N Engl J Med, 2018 Mar 15; 378(11). PMID: 29539277
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.
S Sakaguchi, N Sakaguchi, +2 authors, M Toda.
J Immunol, 1995 Aug 01; 155(3). PMID: 7636184
Highly Cited.
Macrophages: The Road Less Traveled, Changing Anticancer Therapy.
Jennifer L Guerriero.
Trends Mol Med, 2018 Apr 16; 24(5). PMID: 29655673    Free PMC article.
Highly Cited. Review.
Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells.
Jae H Park, Renier J Brentjens.
Discov Med, 2010 Apr 29; 9(47). PMID: 20423671    Free PMC article.
The three Es of cancer immunoediting.
Gavin P Dunn, Lloyd J Old, Robert D Schreiber.
Annu Rev Immunol, 2004 Mar 23; 22. PMID: 15032581
Highly Cited. Review.
Tumor-associated macrophages: from mechanisms to therapy.
Roy Noy, Jeffrey W Pollard.
Immunity, 2014 Jul 19; 41(1). PMID: 25035953    Free PMC article.
Highly Cited. Review.
FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis.
Bin-Zhi Qian, Hui Zhang, +9 authors, Jeffrey W Pollard.
J Exp Med, 2015 Aug 12; 212(9). PMID: 26261265    Free PMC article.
Highly Cited.
Comprehensive genomic characterization of squamous cell lung cancers.
Cancer Genome Atlas Research Network.
Nature, 2012 Sep 11; 489(7417). PMID: 22960745    Free PMC article.
Highly Cited.
A chemokine receptor antagonist inhibits experimental breast tumor growth.
Stephen C Robinson, Kate A Scott, +3 authors, Frances R Balkwill.
Cancer Res, 2003 Dec 18; 63(23). PMID: 14678997
Macrophage biology in development, homeostasis and disease.
Thomas A Wynn, Ajay Chawla, Jeffrey W Pollard.
Nature, 2013 Apr 27; 496(7446). PMID: 23619691    Free PMC article.
Highly Cited. Review.
Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
Ren-You Pan, Wen-Hung Chung, +4 authors, Shuen-Iu Hung.
J Immunol Res, 2019 Jan 22; 2018. PMID: 30662919    Free PMC article.
Review.
The basic principles of chimeric antigen receptor design.
Michel Sadelain, Renier Brentjens, Isabelle Rivière.
Cancer Discov, 2013 Apr 04; 3(4). PMID: 23550147    Free PMC article.
Highly Cited. Review.
Surgery-induced monocytic myeloid-derived suppressor cells expand regulatory T cells in lung cancer.
Jun Wang, Liu Yang, +5 authors, Xiao-San Su.
Oncotarget, 2017 Feb 09; 8(10). PMID: 28178645    Free PMC article.
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.
Martin Sebastian, Alexandros Papachristofilou, +12 authors, Alfred Zippelius.
BMC Cancer, 2014 Oct 08; 14. PMID: 25288198    Free PMC article.
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
Daisuke Sugiyama, Hiroyoshi Nishikawa, +10 authors, Shimon Sakaguchi.
Proc Natl Acad Sci U S A, 2013 Oct 16; 110(44). PMID: 24127572    Free PMC article.
Highly Cited.
Landscape of Tumor Antigens in T Cell Immunotherapy.
Sadia Ilyas, James C Yang.
J Immunol, 2015 Nov 22; 195(11). PMID: 26589749    Free PMC article.
Review.
The role of neoantigen in immune checkpoint blockade therapy.
Ming Yi, Shuang Qin, +3 authors, Kongming Wu.
Exp Hematol Oncol, 2018 Nov 27; 7. PMID: 30473928    Free PMC article.
Highly Cited. Review.
Immune escape mechanisms as a guide for cancer immunotherapy.
Gregory L Beatty, Whitney L Gladney.
Clin Cancer Res, 2014 Dec 17; 21(4). PMID: 25501578    Free PMC article.
Highly Cited. Review.
Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
Jian Li, Wenwen Li, +3 authors, Qi Zhao.
J Hematol Oncol, 2018 Feb 13; 11(1). PMID: 29433552    Free PMC article.
Highly Cited. Review.
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.
M Campoli, S Ferrone.
Oncogene, 2008 Oct 07; 27(45). PMID: 18836468    Free PMC article.
Highly Cited. Review.
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4.
Omar S Qureshi, Yong Zheng, +12 authors, David M Sansom.
Science, 2011 Apr 09; 332(6029). PMID: 21474713    Free PMC article.
Highly Cited.
Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3.
Takahiro Nakagomi, Taichiro Goto, +8 authors, Masao Omata.
Cancers (Basel), 2018 Dec 06; 10(12). PMID: 30513627    Free PMC article.
PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.
Martin A Cheever, Celestia S Higano.
Clin Cancer Res, 2011 Apr 08; 17(11). PMID: 21471425
Highly Cited.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, +13 authors, KEYNOTE-042 Investigators.
Lancet, 2019 Apr 09; 393(10183). PMID: 30955977
Highly Cited.
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.
Stefani Spranger, Riyue Bao, Thomas F Gajewski.
Nature, 2015 May 15; 523(7559). PMID: 25970248
Highly Cited.
Tumor neoantigens: from basic research to clinical applications.
Tao Jiang, Tao Shi, +5 authors, Caicun Zhou.
J Hematol Oncol, 2019 Sep 08; 12(1). PMID: 31492199    Free PMC article.
Highly Cited. Review.
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.
Taku Okazaki, Shunsuke Chikuma, +2 authors, Tasuku Honjo.
Nat Immunol, 2013 Nov 19; 14(12). PMID: 24240160
Highly Cited. Review.
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, +43 authors, Luis A Diaz.
Science, 2017 Jun 10; 357(6349). PMID: 28596308    Free PMC article.
Highly Cited.
Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma.
A Nowicki, J Szenajch, +6 authors, W Wiktor-Jedrzejczak.
Int J Cancer, 1996 Jan 03; 65(1). PMID: 8543387
Neoantigen-directed immune escape in lung cancer evolution.
Rachel Rosenthal, Elizabeth Larose Cadieux, +26 authors, TRACERx consortium.
Nature, 2019 Mar 22; 567(7749). PMID: 30894752    Free PMC article.
Highly Cited.
Developing neoantigen-targeted T cell-based treatments for solid tumors.
Tori N Yamamoto, Rigel J Kishton, Nicholas P Restifo.
Nat Med, 2019 Oct 09; 25(10). PMID: 31591590
Highly Cited. Review.
From Cancer Immunoediting to New Strategies in Cancer Immunotherapy: The Roles of Immune Cells and Mechanics in Oncology.
Virginia Aragon-Sanabria, Gloria B Kim, Cheng Dong.
Adv Exp Med Biol, 2018 Oct 29; 1092. PMID: 30368751
Review.
Paul Ehrlich and O.T. Avery: pathfinders in the search for immunity.
R M Krause.
Vaccine, 1999 Nov 24; 17 Suppl 3. PMID: 10559538
The future of immune checkpoint therapy.
Padmanee Sharma, James P Allison.
Science, 2015 Apr 04; 348(6230). PMID: 25838373
Highly Cited. Review.
Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison.
Science, 1996 Mar 22; 271(5256). PMID: 8596936
Highly Cited.
Identifying neoantigens for use in immunotherapy.
Sharon Hutchison, Antonia L Pritchard.
Mamm Genome, 2018 Sep 01; 29(11-12). PMID: 30167844    Free PMC article.
Review.
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.
Jan P Böttcher, Eduardo Bonavita, +7 authors, Caetano Reis e Sousa.
Cell, 2018 Feb 13; 172(5). PMID: 29429633    Free PMC article.
Highly Cited.
Evolution and dynamics of pancreatic cancer progression.
S Yachida, C A Iacobuzio-Donahue.
Oncogene, 2013 Feb 19; 32(45). PMID: 23416985    Free PMC article.
Review.
Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.
Makoto Miyara, Yumiko Yoshioka, +15 authors, Shimon Sakaguchi.
Immunity, 2009 May 26; 30(6). PMID: 19464196
Highly Cited.
Airway Microbiota as a Modulator of Lung Cancer.
Taichiro Goto.
Int J Mol Sci, 2020 May 03; 21(9). PMID: 32357415    Free PMC article.
Review.
Primary Driver Mutations in GTF2I Specific to the Development of Thymomas.
Rumi Higuchi, Taichiro Goto, +7 authors, Masao Omata.
Cancers (Basel), 2020 Jul 30; 12(8). PMID: 32722121    Free PMC article.
MiR-1231 decrease the risk of cancer-related mortality in patients combined with non-small cell lung cancer and diabetes mellitus.
Jing Li, Jialiang Xu, +2 authors, Luyu Zhang.
Cancer Cell Int, 2020 Sep 18; 20. PMID: 32939184    Free PMC article.
Patient-Derived Tumor Xenograft Models: Toward the Establishment of Precision Cancer Medicine.
Taichiro Goto.
J Pers Med, 2020 Jul 28; 10(3). PMID: 32708458    Free PMC article.
Review.
iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery.
Sujin Kang, Sooyeun Lee, Soyeun Park.
Polymers (Basel), 2020 Aug 28; 12(9). PMID: 32847045    Free PMC article.
Review.
Association of Mutation Profiles with Postoperative Survival in Patients with Non-Small Cell Lung Cancer.
Taichiro Goto, Kei Kunimasa, +8 authors, Masao Omata.
Cancers (Basel), 2020 Nov 26; 12(11). PMID: 33233456    Free PMC article.
Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer.
Panagiota Economopoulou, Ioannis Kotsantis, Amanda Psyrri.
Cancers (Basel), 2020 Nov 19; 12(11). PMID: 33203092    Free PMC article.
Review.
The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
Wen-Juan Tian, Shan-Shan Liu, Bu-Rong Li.
Technol Cancer Res Treat, 2020 Dec 02; 19. PMID: 33256552    Free PMC article.
PLCG2 as a potential indicator of tumor microenvironment remodeling in soft tissue sarcoma.
Zhengtian Li, Rong Zhao, +5 authors, Lingling Jiang.
Medicine (Baltimore), 2021 Mar 18; 100(11). PMID: 33725976    Free PMC article.
Not Only Immune Escape-The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis.
Iwona Kwiatkowska, Justyna Magdalena Hermanowicz, Alicja Przybyszewska-Podstawka, Dariusz Pawlak.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34071442    Free PMC article.
Review.
Mouse lung automated segmentation tool for quantifying lung tumors after micro-computed tomography.
Mary Katherine Montgomery, John David, +6 authors, Anand Giddabasappa.
PLoS One, 2021 Jun 18; 16(6). PMID: 34138905    Free PMC article.
VDAC1 Silencing in Cancer Cells Leads to Metabolic Reprogramming That Modulates Tumor Microenvironment.
Erez Zerbib, Tasleem Arif, +2 authors, Varda Shoshan-Barmatz.
Cancers (Basel), 2021 Jul 03; 13(11). PMID: 34200480    Free PMC article.
NK Cells Lose Their Cytotoxicity Function against Cancer Stem Cell-Rich Radiotherapy-Resistant Breast Cancer Cell Populations.
Hana Jin, Hye Jung Kim.
Int J Mol Sci, 2021 Sep 11; 22(17). PMID: 34502547    Free PMC article.
The Role of Respiratory Microbiota in Lung Cancer.
Dan Wang, Jingyi Cheng, +4 authors, Yongguang Tao.
Int J Biol Sci, 2021 Sep 14; 17(13). PMID: 34512172    Free PMC article.
Review.
Deciphering the Immune-Tumor Interplay During Early-Stage Lung Cancer Development via Single-Cell Technology.
Wei-Wei Chen, Wei Liu, +5 authors, Hanjie Li.
Front Oncol, 2022 Jan 21; 11. PMID: 35047383    Free PMC article.
Review.
A hypoxia-linked gene signature for prognosis prediction and evaluating the immune microenvironment in patients with hepatocellular carcinoma.
Jukun Wang, Yu Li, +3 authors, Tao Luo.
Transl Cancer Res, 2022 Feb 05; 10(9). PMID: 35116696    Free PMC article.
A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy.
Jin Bian, Yan Niu, +2 authors, Ning Ma.
Appl Bionics Biomech, 2022 Feb 08; 2022. PMID: 35126664    Free PMC article.
Serum exosomal proteomics analysis of lung adenocarcinoma to discover new tumor markers.
Shanshan Liu, Wenjuan Tian, +3 authors, Burong Li.
BMC Cancer, 2022 Mar 17; 22(1). PMID: 35291954    Free PMC article.
Analyzing the influence of IL18 in regulation of YAP1 in breast oncogenesis using cBioportal.
Ayesha Rahman, Lingadahalli S Shashidhara.
Cancer Rep (Hoboken), 2021 Jul 02; 5(3). PMID: 34196131    Free PMC article.
COVID-19 in cancer patients.
Suranjith L Seneviratne, Widuranga Wijerathne, Pamodh Yasawardene, Buddhika Somawardana.
Trans R Soc Trop Med Hyg, 2022 Mar 12;. PMID: 35276734    Free PMC article.
Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.
Alicia Cristina Peña-Romero, Esteban Orenes-Piñero.
Cancers (Basel), 2022 Apr 13; 14(7). PMID: 35406451    Free PMC article.
Review.